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based on the number of resections with curative intent for 
pancreatic cancer. Independent predictors of administra-
tion of palliative chemotherapy were evaluated by means of 
logistic regression analysis. The multivariable Cox propor-
tional hazard model was used to assess the impact of being 
diagnosed or treated in high-volume centers on survival.
Results A total of 5385 patients presented with meta-
static pancreatic cancer of which 24 % received palliative 
chemotherapy. Being treated with chemotherapy in a high-
volume chemotherapy treatment center was associated with 
improved survival (HR 0.76, 95 % CI 0.67–0.87). Also, in 
all patients with metastatic pancreatic cancer, being diag-
nosed in a high-volume surgical center was associated with 
improved survival (HR 0.74, 95 % CI 0.66–0.83).
Conclusions Hospital volume of palliative chemother-
apy for metastatic pancreatic cancer was associated with 
improved survival, demonstrating that a volume–outcome 
relationship, as described for pancreatic surgery, may also 
exist for pancreatic medical oncology.
Keywords Pancreatic cancer · High-volume hospital · 
Palliative chemotherapy · Survival · Population based
Introduction
The incidence of pancreatic cancer is rising in developed 
countries. In 2012 alone, 104,481 individuals died from 
pancreatic cancer making it the fifth leading cause of can-
cer death with the worst overall survival (European Cancer 
Observatory 2012). By 2030, pancreatic cancer is projected 
to become the second leading cause of cancer-related death 
(Rahib et al. 2014). The only potentially curative treatment 
for pancreatic cancer is surgical resection. However, only 
about 20 % of the patients present with resectable disease. 
Abstract 
Purpose In pancreatic surgery, a relation between surgi-
cal volume and postoperative mortality and overall sur-
vival (OS) has been recognized, with high-volume centers 
reporting significantly better survival rates. We aimed to 
explore the influence of hospital volume on administration 
of palliative chemotherapy and OS in the Netherlands.
Methods Patients diagnosed between 2007 and 2011 with 
metastatic pancreatic cancer were identified in the Nether-
lands Cancer Registry. Three types of high-volume cent-
ers were defined: high-volume (1) incidence center, based 
on the number of patients diagnosed with metastatic pan-
creatic cancer, (2) treatment center based on number of 
patients with metastatic pancreatic cancer who started treat-
ment with palliative chemotherapy and (3) surgical center 
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Patients not fit enough to undergo surgery or patients 
with irresectable or metastatic tumors have a poor prog-
nosis with a median survival of about three months when 
untreated (Royal 2011). In 1997, gemcitabine monotherapy 
became the first-line standard treatment. In numerous tri-
als over the years, many different drug regimens have been 
tested. None of these trials demonstrated a statistically sig-
nificant survival benefit, except for gemcitabine plus erlo-
tinib, which was associated with a very modest, clinically 
irrelevant increase in overall survival of 2 weeks (Moore 
et al. 2007). Only recently two trials changed the landscape 
of palliative pancreatic cancer treatment, showing a sub-
stantial improvement in survival after combination chemo-
therapy (Conroy et al. 2011; Von Hoff et al. 2013; Gold-
stein et al. 2015).
The scarce availability of treatment options may have 
led to reserved prescription as well as heterogeneity in 
prescription of palliative chemotherapy between hospi-
tals. Indeed, a recently published study conducted in the 
Netherlands showed a large inter-hospital variation in the 
administration of chemotherapy (5–34 %) to patients with 
metastatic pancreatic carcinoma (Bernards et al. 2015). The 
most frequently mentioned reasons for not offering pallia-
tive chemotherapy were the age and socioeconomic status 
of the patient (Krzyzanowska et al. 2003; Kao et al. 2009). 
Furthermore, preferences and experience of medical oncol-
ogists may play an important role in the choice to start pal-
liative therapy (Schildmann et al. 2013). The willingness 
to apply a treatment which may have limited benefit and 
potential side effects has been related to the annual num-
ber of patients qualifying for such treatment by a physician 
(Krammer and Heinzerling 2014).
In pancreatic surgery, a direct relation between the num-
ber of operated patients in a hospital and postoperative 
outcome has been established, with postoperative mortal-
ity after pancreaticoduodenectomy being significantly 
lower in high-volume compared to low-volume hospitals 
(Birkmeyer et al. 1999; Gooiker et al. 2011, 2014; Tol 
et al. 2012). Interestingly, in this relation between volume 
and outcome the overall hospital volume has been shown 
to be even more relevant than the volume of patients 
treated per individual surgeon (Gouma et al. 2000), indi-
cating the importance of experienced non-surgical sup-
port for this specific group of patients. Similarly, it may be 
hypothesized that for treatment of patients with metastatic 
cancer, the experience of medical oncologists, as defined 
by the number of annually treated patients, as well as the 
combined experience of the whole multidisciplinary team 
providing pancreatic cancer care may be a relevant factor 
determining patient outcome.
Recently, in 245 patients with resectable pancreatic 
cancer a superior survival was found for patients being 
treated with adjuvant chemotherapy in a high-volume 
hospital compared to patients treated in a low-volume hos-
pital (Mandelson and Picozzi 2016). These data were pre-
sented at ASCO Gastrointestinal Cancers Symposium 2016 
and underline that further elaboration is necessary on dif-
ferences in patterns of care and their impact on survival.
To our knowledge, no information is available on the 
relation between volume and survival of patients with 
metastatic pancreatic cancer. Therefore, we conducted a 
nationwide population-based study in patients with meta-
static pancreatic cancer to assess whether volume is a pre-
dictor for (1) the percentage of patients receiving palliative 
chemotherapy and (2) overall survival.
Methods
Data collection
Data were obtained from the Netherlands Cancer Registry 
(NCR). This is a population-based prospective database 
that collects information on all patients newly diagnosed 
with a malignancy in the Netherlands. The registry area 
includes about 16.7 million inhabitants and encompasses 
91 hospitals, of which eight academic. The NCR is noti-
fied by the national automated pathological archive, if the 
newly diagnosed cancer is microscopically verified. In the 
absence of verification, notification occurs by additional 
sources, such as the national registry of hospital discharge, 
multidisciplinary team reports and diagnosis therapy com-
binations (specific codes for reimbursement purposes). 
Within 6–9 months after notification, trained registration 
clerks, operating on behalf of the NCR, extract patient and 
tumor characteristics from medical records. Data are coded 
according to a national manual, and cancer topography and 
morphology are classified according to the International 
Classification of Disease for Oncology (ICD-O) second or 
third edition.
Our inclusion was limited to patients diagnosed with 
an adenocarcinoma, a not otherwise specified carcinoma 
(ICD-O morphology codes 8010, 8012, 8020, 8140,8141, 
8260, 8310, 8440, 8470, 8480, 8481, 8490, 8500, 8560) 
or a non-microscopic verified neoplasm of the pancreas 
between January 2007 and December 2011. Other mor-
phology codes were excluded or did not occur during the 
study period. Patients diagnosed at autopsy were excluded. 
Carcinomas were classified according to the Tumor Lymph 
Node Metastases classification and staged according to the 
recommendations of the International Union Against Can-
cer (UICC) TNM classification in the respective period. For 
staging of neoplasm without microscopic verification, the 
clinical extent of disease (cEOD) was used.
To assess the influence of hospital volume on outcome, 
we defined high-volume centers based on the upper quartile 
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(Q3/75th percentile). Each volume threshold dichoto-
mized the data and created two categories for comparison: 
hospitals with volume greater or equal to the cutoff value 
and hospitals with volume less than the cutoff value. We 
defined three different types of high-volume centers.
1. High-volume incidence center: a hospital volume that 
refers to the number of patients diagnosed with meta-
static pancreatic cancer. This may be regarded the most 
straightforward hospital volume. However, as pan-
creatic cancer treatment may be an important deter-
minant of outcome of pancreatic cancer patients and 
a high-volume incidence center does not necessarily 
treat a high volume of patients, we also identified high-
volume treatment center; ≥101 patients diagnosed in 
5 years (range 14–183);
2. High-volume treatment center: a hospital volume that 
refers to the number of metastatic pancreatic can-
cer patients treated with chemotherapy. This may be 
regarded as a proxy for the experience of a hospital to 
deliver care to this patient population that may develop 
specific complications in this disease stage; ≥28 
patients treated in 5 years (range 1–116);
3. High-volume surgical center: a hospital volume which 
refers to the number of surgical procedures in pancre-
atic cancer, which may be regarded as a proxy for the 
presence of a well-developed infrastructure to deliver 
complex care to pancreatic cancer patients; ≥68 resec-
tions with curative intent treated in 5 years (range 
1–123).
Vital status of all patients on January 1, 2014, was 
assessed through linkage with civil municipal registries and 
the Central Bureau for Genealogy, which collects data on 
all citizens who die.
Statistical analysis
We performed all statistical analyses using SAS statisti-
cal software (version 9.4, SAS institute, Cary, NC, USA). 
Two sided P values of <0.05 were considered statistically 
significant.
The proportion of patients treated with chemotherapy 
was described for different subgroups and high-volume 
centers. Differences between subgroups were tested by 
means of a χ2 test, and trends overtime were analyzed by 
means of a Cochran–Armitage trend test. Independent 
influences on prescription of palliative chemotherapy were 
evaluated by means of a logistic regression analysis. The 
different types of high-volume centers were added sepa-
rately to the model.
Survival time was defined as the time from diagnosis 
to death or January 1, 2014, for patients who were still 
alive. The crude survival was calculated with the life test, 
and differences between survival curves were evaluated by 
means of a log-rank test. The independent prognostic effect 
of being diagnosed or treated in a high-volume center was 
estimated using Cox regression analyses.
The hazard rates for death were adjusted for gender, age, 
extent of disease and period of diagnosis. The influence 
of being diagnosed in a high-volume treatment center was 
investigated in patients treated with chemotherapy only; 
untreated patients were excluded from this analysis. In the 
other models chemotherapy was added separately to inves-
tigate the effect of treatment on the hazard ratio of death.
Results
Between January 1, 2007, and December 31, 2011, 9981 
patients were diagnosed with pancreatic cancer in the 
Netherlands, of whom 5385 (54 %) patients presented 
with metastatic disease. The patient selection is shown in 
Fig. 1. Fifty-two percent of the patients with metastatic dis-
ease were male, the median age at time of diagnosis was 
69 years (range 21–100), and in 68 % of the cases the diag-
nosis was microscopically confirmed. The general char-
acteristics of patients treated in high-volume centers are 
shown in Table 1.
We defined high-volume centers, based on three differ-
ent volume thresholds. In, total, 17 hospitals were classi-
fied as a high-volume center. Thirteen hospitals were clas-
sified as high-volume incidence center, seven hospitals as 
high-volume treatment center, and four hospitals as high-
volume surgical center. Only one hospital qualified for all 
three high-volume definitions. Another four high-volume 
incidence centers were also high-volume treatment centers.
Twenty-four percent (N = 1274) of the patients with 
metastatic pancreatic cancer received palliative chemother-
apy. Table 2 shows the crude proportions of patients treated 
with chemotherapy in the different high-volume centers. 
The odds of receiving palliative chemotherapy were higher 
in high-volume treatment centers. Palliative chemotherapy 
was not administered more often in high-volume incidence 
centers or high-volume surgical centers. Other predictive 
factors for prescription of chemotherapy were younger age 
at time of diagnosis, the presence of microscopic verifica-
tion [OR 3.13 (2.63–3.85)], two sites of metastases [OR 
0.73 (0.57–0.94)] and a more recent year of diagnosis [OR 
for 2011, 2007 reference 1.55 (1.24–1.94)].
We found that patients diagnosed in the hospital that 
qualified for all three high-volume definitions had PA 
verification more often compared to patients that were 
diagnosed in a hospital that was only one type of high-
volume center (supplementary table 1). However, patients 
in that specific hospital were not treated with palliative 
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chemotherapy more frequently compared to other high-
volume hospitals.
The median overall survival of patients with metastatic 
pancreatic cancer was 9.6 weeks (1-year survival rate 6 %). 
Table 3 shows the results of a multivariable proportional 
hazard regression analysis modeling the risk of death for 
patients with metastatic pancreatic cancer. Factors that were 
associated with poor survival were older age (≥80 years), 
the absence of microscopic verification and metastases in 
multiple organs. Metastases limited to the lungs or lim-
ited to extra regional lymph nodes, treatment with pallia-
tive chemotherapy and treatment in a high-volume surgical 
center were identified as beneficial prognostic factors. By 
excluding treatment with chemotherapy from the model 
(result not shown), the beneficial effect of younger age was 
statistically significant.
The median overall survival in patients treated with pal-
liative chemotherapy was 24 weeks (1-year survival rate 
(14 %). Multivariable hazard regression analysis in patients 
treated with palliative chemotherapy revealed that being 
treated in a high-volume treatment center was associated 
with improved survival (HR 0.76, 95 % CI 0.67–0.87) 
(Table 3).
Discussion
To the best of our knowledge, this is the first study showing 
a positive correlation between hospital volume and overall 
survival in patients with metastatic pancreatic cancer. The 
population-level findings demonstrate that being diagnosed 
in a high-volume surgical center and being treated with pal-
liative chemotherapy in a high-volume treatment center are 
associated with improved survival.
The presence of microscopic verification of (metastatic) 
pancreatic cancer, as well as younger age, is well-known 
and established predictors for starting palliative chemother-
apy (Krzyzanowska et al. 2003). However, hospital volume 
(high-volume treatment center) as a predictor for starting 
palliative chemotherapy has never been reported before. 
Patients that were treated with palliative chemotherapy in 
a center that had a high treatment volume of pancreatic 
cancer patients exhibited a better survival than patients 
that were treated with palliative chemotherapy in other 
hospitals.
The association between high-volume treatment center 
and prolonged survival may be explained by the experience 
of high-volume treatment centers with this specific patient 
Fig. 1  Flow diagram of 
included patients. NNO not 
otherwise specified
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population and specific chemotherapy treatment. Already 
in 1979, Luft et al. (1979) described for pancreatic surgery 
an inverse relation between surgical volume and mortal-
ity. Since centralization of pancreatic surgery, a relation 
between surgical volume, postoperative mortality and 
overall survival has been demonstrated, with high-volume 
surgical centers reporting significantly better survival rates 
(Birkmeyer et al. 2002; van Oost et al. 2006; Gooiker et al. 
2011).
In metastatic disease, the medical oncologist has to weigh 
patient’s prognosis, treatment toxicity and the possible posi-
tive impact on quality or quantity of life and together with 
the patient decide to start palliative chemotherapy or to pro-
vide supportive care only. Given the often poor clinical con-
dition of pancreatic cancer patient which may deteriorate 
rapidly, this decision making process is not trivial. Moreo-
ver, when starting palliative chemotherapy, toxicity has to 
be managed adequately, including appropriate reductions in 
chemotherapy dose, without stopping treatment either too 
early or too late. Hence, experience in treating this patient 
population, acquired by treating a relatively high number of 
patients, may be of paramount importance for the outcome 
of these patients. Furthermore, we hypothesize that not only 
the expertise of an individual medical oncologist, but also 
the complete infrastructure of the hospital may relate to 
patient outcome (Wolfson et al. 2015).
Table 1  General characteristics of patients diagnosed with a neoplasm of the pancreas between 2007 and 2011 in the Netherlands, stratified 










 Male 2796 (52) 825 (54) 455 (55) 215 (59)
 Female 2589 (48) 707 (46) 380 (46) 148 (41)
Age (years)
 <50 239 (4) 68 (4) 47 (6) 29 (8)
 50–59 817 (15) 228 (15) 140 (17) 83 (23)
 60–69 1671 (31) 505 (33) 302 (36) 131 (36)
 70–79 1731 (32) 471 (31) 250 (30) 97 (27)
 ≥80 927 (17) 260 (17) 96 (12) 23 (6)
Histologic subtype
 Adenocarcinoma 3640 (68) 1082 (71) 659 (79) 312 (86)
 Non-microscopic verified 1745 (32) 450 (29) 176 (21) 51 (14)
Location of metastases
 Liver 2770 (51) 775 (51) 407 (49) 168 (46)
 Peritoneum 425 (8) 110 (7) 54 (7) 36 (10)
 Lung 244 (5) 66 (4) 36 (4) 14 (4)
 Extra regional lymphnodes 179 (3) 61 (4) 38 (5) 27 (7)
 Other 100 (2) 25 (2) 18 (2) 7 (2)
 2 organs 1190 (22) 340 (22) 199 (24) 84 (23)
 3 or more organs 431 (8) 131 (9) 73 (9) 23 (6)
Chemotherapy
 Yes 1274 (24) 400 (26) 329 (39) 100 (28)
 No 4111 (76) 1132 (74) 506 (61) 263 (73)
 Total 5385 (100) 1532 (28) 835 (16) 363 (7)
Table 2  Crude percentages and adjusted odds for receiving chemo-
therapy among patients diagnosed with metastatic pancreatic cancer 
between 2007 and 2011 in the Netherlands (N = 5385)
a Different types of high-volume centers were added separately to the 
model adjusted for tumor and patient characteristics
Crude percentage % Multivariate odds ratio (95 % CI)
Diagnosed in high-volume incidence centera
 Yes 26 1.14 (0.98–1.32)
 No 23 1.00 (reference)
Treated in high-volume treatment centera
 Yes 39 2.20 (1.85–2.61)
 No 21 1.00 (reference)
Diagnosed in high-volume surgical centera
 Yes 28 0.82 (0.64–1.07)
 No 23 1.00 (reference)
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Specific tumor and treatment-related complications such 
as pain management, nutritional care and biliary drainage 
request comprehensive care. For example, cholangitis due 
to compression of the bile ducts and duodenal obstruction 
by a cancer in the pancreatic head is common in patients 
with metastatic cancer. Decompression has shown to 
improve quality of life and may improve survival (Ballinger 
et al. 1994; Chu and Adler 2010). A yearly volume of ≥50 
ERCPs per endoscopist was significantly associated with a 
lower risk of procedural failure (Ekkelenkamp et al. 2015). 
Our population-level finding that for all patients with meta-
static pancreatic cancer, being diagnosed in a high-volume 
surgical center and high-volume treatment center was asso-
ciated with improved survival, suggests that an experienced 
multidisciplinary team may contribute to optimal treatment 
of metastatic pancreatic cancer.
The prognosis of patients with pancreatic cancer remains 
poor with a median survival of 9.6 weeks. It is difficult to 
compare this result with the outcome of randomized con-
trolled trials, which show higher survival rates due to inclu-
sion of relatively young patients with a good performance 
status. However, the median duration in survival that we 
observed was comparable to another population-based 
study (Baxter et al. 2007) but lower than other population-
based studies, albeit marginally (Cress et al. 2006; Worni 
et al. 2013). This may be explained by the inclusion of 
pathologically unverified carcinomas in our study. A sig-
nificant portion of patients did not have their diagnosis con-
firmed by pathological examination; possibly because these 
patients were considered unfit for palliative chemotherapy 
and pathological confirmation would not have had thera-
peutic implications. The overall survival of these patients 
was 7 weeks, and therefore, the likelihood that these 
patients indeed suffered from pancreatic cancer is high. 
In our series, 24 % of the patients with metastatic pancre-
atic cancer were treated with palliative chemotherapy. The 
reported percentage in previous population-based studies 
in metastatic pancreatic is highly variable. Moreover, the 
presented specific subsets of patients treated with pallia-
tive chemotherapy were inconsistent. David et al. (2009) 
described 30 % of the patients receiving palliative chem-
otherapy after palliative surgery. In non-resected patients, 
the use was only 17 %. Sharp et al. (2009) reported 20 %. 
One Australian cohort observed that 43 % of the patients 
received palliative chemotherapy; however, this was a 
smaller study with 1863 patients and selection bias may 
have occurred (Burmeister et al. 2015). A second Austral-
ian study by Jefford et al. (2010) reported 54 % chemo-
therapy use, but analyzed both resectable and irresectable 
patients. A recent study by Oberstein et al. (2013) seems to 
report a considerably higher percentage of patients treated 
with palliative chemotherapy (54 %). However, patients 
who died within 30 days (22 %) were excluded from the 
analysis. This implies that 42 % was treated with palliative 
chemotherapy. Median survival in patients treated with pal-
liative chemotherapy was 24 weeks. This corresponds well 
with previously published data from the south of the Neth-
erlands (Bernards et al. 2015). Similar to previous studies, 
we found that younger age and limited metastases were 
related to better survival (Cress et al. 2006; Tas et al. 2013).
It should be noted that this analysis was conducted in the 
era before FOLFIRINOX and nab-paclitaxel with gemcit-
abine. With the introduction of the two new combination 
regimens for metastatic pancreatic cancer, FOLFIRINOX 
and nab-paclitaxel with gemcitabine, experience of the 
medical oncologist may become even more important. The 
combination therapies have different efficacies, different 
side effects and different routes of administration (Conroy 
et al. 2011; Von Hoff et al. 2013; Goldstein et al. 2015). 
As there are no direct data comparing the two combina-
tion treatment regimens, experience with all known pallia-
tive treatment options is of utmost importance to select the 
appropriate treatment for each individual patient. Because 
of the higher toxicity of the combination therapy, few 
Table 3  Crude median overall 
survival, crude 1-year survival 
and adjusted hazard ratios 
for patients diagnosed with 
metastatic pancreatic cancer 
between 2007 and 2011 in the 
Netherlands (N = 5385)
a Different types of high-volume centers were added separately to the model adjusted for all the above 
listed variables
b Only patients treated with palliative chemotherapy were included in the analysis (N = 1274)
Crude median survival (weeks) Crude 1-year survival (%) Multivariable HR (95 % CI)
Diagnosed in high-volume incidence centera
 Yes 9.9 6.7 0.86 (0.94–1.06)
 No 9.4 5.5 1.00 (reference)
Treated in high-volume treatment centera,b
 Yes 28.4 21.3 0.76 (0.67–0.87)
 No 22.9 11.6 1.00 (reference)
Diagnosed in high-volume surgical centera
 Yes 14.7 11.9 0.74 (0.66–0.83)
 No 9.3 5.4 1.00 (reference)
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patients will be considered fit for the combination regimen 
and, as a consequence, the experience per center with a 
specific regimen may further decrease. Thus, concentration 
of medical oncological care for patients with metastatic 
pancreatic cancer may become even more important.
It should be acknowledged that even with very careful 
analysis of population-based data it cannot be excluded that 
part of our results are explained by selection bias. Patients 
treated in high-volume surgical centers may be a selection 
of fit patients with limited metastatic tumor load. Part of 
these patients may initially have been considered resectable 
while during explorative laparotomy patients were shown to 
have irresectable disease, for instance due to small peritoneal 
metastases. Also, it may be argued that younger, fitter patients 
select high-volume hospitals. To minimize the confounding 
effect of palliative chemotherapy itself only patients were 
analyzed that were treated with palliative chemotherapy. Yet, 
other confounders related to usage of palliative chemotherapy 
cannot be ruled out. However, after adjustment for patient 
and tumor characteristics, we showed that survival was better 
in high-volume treatment centers. Unfortunately, we did not 
have information on performance status available in our data-
set (Boeck et al. 2007). This lack of information on perfor-
mance status is a significant limitation of our study. Further-
more, the hospital volumes that we defined in our study need 
validation, and from these data no definite conclusions can 
be drawn on whether a specific type of high-volume center 
should be the norm for best clinical practice.
In conclusion, in this nationwide database, hospital 
volume of palliative chemotherapy was associated with 
improved survival demonstrating that a volume–outcome 
relationship, as described for pancreatic surgery, may also 
exist for pancreatic medical oncology.
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